Scarica l'app Stockscreener
22.91
2.51%
0.56
Dopo l'orario di chiusura:
22.91
Precedente Chiudi:
$22.35
Aprire:
$22.75
Volume 24 ore:
86,086
Relative Volume:
1.22
Capitalizzazione di mercato:
$960.96M
Reddito:
-
Utile/perdita netta:
$-75.28M
Rapporto P/E:
-11.48
EPS:
-1.9957
Flusso di cassa netto:
$-57.45M
1 W Prestazione:
+1.78%
1M Prestazione:
+34.76%
6M Prestazione:
+97.50%
1 anno Prestazione:
+76.23%
Intervallo 1D:
$22.75
$23.01
Intervallo di 1 settimana:
$21.87
$23.01
Portata 52W:
$10.55
$23.08
Oculis Holding Ag Stock (OCS) Company Profile
Nome
Oculis Holding Ag
Settore
Industria
Telefono
-
Indirizzo
-
Confronta OCS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
22.91 | 960.96M | 0 | -75.28M | -57.45M | -1.9957 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-05 | Iniziato | Chardan Capital Markets | Buy |
| 2023-10-05 | Iniziato | Stifel | Buy |
| 2023-06-14 | Iniziato | BofA Securities | Buy |
| 2023-06-12 | Iniziato | H.C. Wainwright | Buy |
| 2023-06-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-10 | Iniziato | Pareto | Buy |
| 2023-04-28 | Iniziato | Wedbush | Outperform |
Mostra tutto
Oculis Holding Ag Borsa (OCS) Ultime notizie
Oculis updates share capital for its existing at-the-market offering program - The Manila Times
Oculis Secures Financial Flexibility: Strategic $100M ATM Program Backed by 2.5M Fresh Shares - StockTitan
Here's Why Momentum in Oculis Holding AG (OCS) Should Keep going - MSN
Trend Tracker for (OCS) - Stock Traders Daily
Oculis Announces Significant Voting Rights Changes Following Íslandsbanki Activity - StockTitan
Oculis Is An Interesting Growth Bet On Non-Invasive Eye Care (NASDAQ:OCS) - Seeking Alpha
Oculis Announces Major Voting Rights Changes Involving Íslandsbanki in Switzerland - StockTitan
(OCS) Proactive Strategies - Stock Traders Daily
Here's What Could Help Oculis Holding AG (OCS) Maintain Its Recent Price Strength - MSN
Oculis (NASDAQ:OCS) Reaches New 12-Month HighTime to Buy? - MarketBeat
Oculis (NASDAQ:OCS) Shares Gap Up – Here’s Why - Defense World
Head to Head Comparison: Oculis (NASDAQ:OCS) vs. Immunome (NASDAQ:IMNM) - Defense World
Accure Therapeutics partner Oculis reached positive phase 2 results for lead neuroprotective therapy - MENAFN.COM
Oculis (NASDAQ:OCS) Shares Gap UpWhat's Next? - MarketBeat
Trading (OCS) With Integrated Risk Controls - Stock Traders Daily
Chardan Capital Reiterates Buy Rating for Oculis (NASDAQ:OCS) - Defense World
Oculis (NASDAQ:OCS) Sees Large Volume IncreaseHere's Why - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Oculis (NASDAQ:OCS) - Defense World
Oculis' (OCS) "Buy" Rating Reiterated at Chardan Capital - MarketBeat
Oculis reiterates shares target, buy rating post-trial - Investing.com
Stifel maintains Oculis stock Buy rating, $35 target post-study - Investing.com India
Oculis Trial Shows Potential for Optical Neuroprotective Therapy - Yahoo Finance
Oculis Holding’s OCS-05 Shows Promising Results in Phase 2 Trial for Acute Optic Neuritis - TipRanks
Stifel maintains Oculis stock Buy rating, $35 target post-study By Investing.com - Investing.com South Africa
Oculis' (OCS) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Oculis presents 'groundbreaking' data in optic neuritis with OCS-05 - BioWorld Online
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential... - Markets Insider
OCSOculis Holding AG Ordinary shares Latest Stock News & Market Updates - StockTitan
Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy - The Manila Times
Oculis' OCS-05 Shows Breakthrough 43% Vision Improvement in Phase 2 Optic Neuritis Trial - StockTitan
Oculis Phase 2 Trial Shows 43% Vision Improvement in Optic Neuritis Treatment Breakthrough - StockTitan
Oculis Publishes Notification of Major Changes in Voting Rights - The Manila Times
Oculis Holding Announces Major Voting Rights Restructure as Key Shareholder Redistributes Stakes - StockTitan
Oculis Holding (OCS): A Biopharma Opportunity for Adventurous Investors - TipRanks
(OCS) Investment Analysis and Advice - Stock Traders Daily
Oculis (NASDAQ:OCS) Sees Unusually-High Trading Volume – Here’s Why - Defense World
Oculis (NASDAQ:OCS) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
(OCS) Investment Report - Stock Traders Daily
Oculis Directors Complete RSU Vesting Transaction in Strategic Stock Move - StockTitan
Oculis Holding AG (NASDAQ:OCS) Short Interest Update - MarketBeat
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated - Marketscreener.com
Oculis Announces Major Share Vesting Event for Key Executives | OCS Stock News - StockTitan
Where are the Opportunities in (OCS) - Stock Traders Daily
Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities - Marketscreener.com
Oculis Awards Equity Incentive to Director Arshad Khanani for Consulting Services | OCS Stock News - StockTitan
Oculis (NASDAQ:OCS) Shares Up 3.8%Here's Why - MarketBeat
(OCS) Investment Analysis - Stock Traders Daily
Is Oculis Holding (OCS) Top Performing European Stock Heading into 2025? - Insider Monkey
Oculis to Present at the Stifel 2024 Healthcare Conference - The Manila Times
Oculis (OCS) to Present at Stifel Healthcare Conference: CFO Fireside Chat Announced | OCS Stock News - StockTitan
Oculis Holding Ag Azioni (OCS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):